SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-22-027321
Filing Date
2022-11-14
Accepted
2022-11-14 16:34:22
Documents
69
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q navb20220930_10q.htm   iXBRL 10-Q 1590287
2 EXHIBIT 31.1 ex_443229.htm EX-31.1 8462
3 EXHIBIT 31.2 ex_443230.htm EX-31.2 8483
4 EXHIBIT 32.1 ex_443231.htm EX-32.1 4320
5 EXHIBIT 32.2 ex_443232.htm EX-32.2 4245
  Complete submission text file 0001437749-22-027321.txt   7703104

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA navb-20220930.xsd EX-101.SCH 64018
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20220930_cal.xml EX-101.CAL 42821
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20220930_def.xml EX-101.DEF 515334
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20220930_lab.xml EX-101.LAB 401567
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20220930_pre.xml EX-101.PRE 536752
63 EXTRACTED XBRL INSTANCE DOCUMENT navb20220930_10q_htm.xml XML 1227923
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 221386533
SIC: 2835 In Vitro & In Vivo Diagnostic Substances